A novel low-dose triple single-pill combination for hypertension

Affiliations

¹ Spili Primary Care Centre, Crete Regional Health System, Rethymno 74053, Greece. Electronic address: antonopm@uoc.gr.
² Agia Fotini Primary Care Centre, Crete Regional Health System, Rethymno 74053, Greece.

Comment

Maria Antonopoulou et al. Lancet. 2024.

. 2024 Oct 19;404(10462):1496-1498.

doi: 10.1016/S0140-6736(24)02072-5.

¹ Spili Primary Care Centre, Crete Regional Health System, Rethymno 74053, Greece. Electronic address: antonopm@uoc.gr.
² Agia Fotini Primary Care Centre, Crete Regional Health System, Rethymno 74053, Greece.

No abstract available

Conflict of interest statement

We declare no competing interests.

Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee DE, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr, Lakshman P, Uluwattage W, Hay P, Pereira T, Amarasena N, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Gnanenthiran SR, Whelton PK; GMRx2 Investigators. Rodgers A, et al. Lancet. 2024 Oct 19;404(10462):1536-1546. doi: 10.1016/S0140-6736(24)01744-6. Lancet. 2024. PMID: 39426836 Clinical Trial.